Antibodies
27 September 2022
Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-227 September 2022
First Patient Enrolled in ProstACT TARGET Study27 September 2022
Angel Pharmaceuticals Announces Approval of IND Application for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China27 September 2022
Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke23 September 2022
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides23 September 2022
Ultomiris approved in Europe for the treatment of adults with generalised myasthenia gravis22 September 2022
Almirall announces the initiation of a phase I study of anti-IL-1RAP first-in-class monoclonal antibody for autoimmune dermatological diseases21 September 2022
Tezspire approved in the EU for the treatment of severe asthma20 September 2022
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China20 September 2022
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-1920 September 2022
European Medicine Agency Accepts Marketing Authorization Applications for Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis19 September 2022
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND19 September 2022
Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial15 September 2022
Transcenta Received IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors13 September 2022
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 202213 September 2022
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced MelanomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports